In Q1 FY2026, BillionToOne reported revenue of $108.4M, up 83.8% year-over-year. Net income was $18.0M, a significant improvement from the prior year. Operating income reached $17.8M, and diluted EPS was $0.34. The company held $537.5M in cash and $505.6M in equity, with long-term debt of $90.0M.
•Revenue grew 83.8% YoY to $108.4M.
•Net income turned positive at $18.0M, up 550.6% YoY.
•Operating income was $17.8M, up 870.4% YoY.
•Diluted EPS of $0.34, up 187.2% YoY.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw.
Its portfolio also includes Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations, and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. Incorporated in 2016, BillionToOne is headquartered in Menlo Park, California.
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create advanced molecular diagnostics. Its core technology is a molecular counting platform designed to detect and measure DNA molecules at the single-count level, enhancing disease detection. The company's main products include UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw. In oncology, BillionToOne offers Northstar Select, a liquid biopsy test that identifies tumor mutations such as deletions, insertions, and point mutations, and Northstar Response, a methylation-based assay that quantifies cancer at the single-molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy.
Where is BillionToOne listed and what currency does it trade in?
BillionToOne, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BLLN. The company trades in United States Dollars (USD), as it is headquartered in the United States and its primary listing is on a U.S. exchange. Investors can buy and sell shares of BillionToOne on the NasdaqGS during regular trading hours, and the stock is denominated in USD, which is the standard currency for U.S. equity markets.
What sector and industry does BillionToOne operate in?
BillionToOne operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company is involved in developing and providing diagnostic tests and research tools that help detect and monitor diseases. As a precision diagnostics company, BillionToOne focuses on molecular diagnostics, which analyze genetic material to identify conditions such as genetic disorders and cancer. Its products are used by healthcare providers for prenatal screening and oncology monitoring, placing it at the intersection of healthcare services and advanced biotechnology research.
Where is BillionToOne headquartered and what markets does it serve?
BillionToOne is headquartered in Menlo Park, California, United States. The company serves the U.S. market primarily, as indicated by its listing on a U.S. exchange and its focus on the American healthcare system. Its products, such as UNITY Complete and the Northstar liquid biopsy tests, are designed for use by healthcare providers and patients in the United States. While the company's precision diagnostics platform has global potential, its current operations and market presence are centered in the U.S., leveraging its location in the San Francisco Bay Area, a hub for biotechnology innovation.
What are the key products in BillionToOne's portfolio?
BillionToOne's portfolio includes several key diagnostic products. UNITY Complete is a non-invasive prenatal screen that assesses fetal risk for aneuploidies (like Down syndrome), recessive genetic conditions, and fetal antigens from a simple maternal blood draw. In oncology, the company offers Northstar Select, a liquid biopsy test that identifies a list of mutations present in a tumor, including deletions, insertions, and point mutations. Another oncology product is Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single-molecule level without needing a tissue biopsy, allowing real-time monitoring of a patient's response to therapy. These products leverage the company's molecular counting platform to provide precise, actionable insights for clinicians.